Anti-Human CD38 (Isatuximab) (C3140-50mg)

CD38 is a multifunctional cell surface protein with key roles in calcium signaling and nicotinamide adenine dinucleotide (NAD+) metabolism. It is expressed at low levels in various tissues but is highly expressed in plasma cells and plasma cell-derived neoplasms like multiple myeloma. CD38 has become an important therapeutic target, especially in multiple myeloma, where monoclonal antibodies such as daratumumab and isatuximab have shown significant efficacy. These antibodies work by inducing cell death through mechanisms like complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity. Given its diverse functions, CD38 is also being explored as a therapeutic target in conditions beyond hematological malignancies, including autoimmune diseases and infections1-3. Isatuximab (SAR-650984) is an anti-CD38 monoclonal antibody that was generated by immunizing mice with 300-19 cells transfected to express the full-length human CD38 antigen followed by humanization by variable domain resurfacing6. It has demonstrated significant efficacy in treating multiple myeloma. It induces tumor cell death through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Clinical trials have shown its effectiveness in improving rates of minimal residual disease negativity in patients with newly diagnosed, transplantation-eligible multiple myeloma, as well as in those with relapsed or refractory disease. Isatuximab is generally well-tolerated, with the most common side effects being manageable infusion reactions4,5.